Cytokinetics Quarterly Balance Sheet
NASDAQ: CYTKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cytokinetics financial position
As of Jun 30, 2026, Cytokinetics reported total assets of $1.92 billion, up 57.0% from a year earlier against total liabilities of $2.10 billion. Shareholders' equity was negative at -$173.5 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $255.3 million in cash and equivalents against $275.6 million of debt, a net debt position of $20.3 million.
The current ratio (current assets divided by current liabilities) was 6.66, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Cytokinetics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 255.27M | 129.84M | 122.52M | 225.47M | 74.94M | 73.68M | 94.86M | 46.89M | 190.14M | 119.98M | 113.02M | 99.69M |
| Short-Term Investments | 910.41M | 688.71M | 759.70M | 737.07M | 783.20M | 864.54M | 981.16M | 964.80M | 866.63M | 498.99M | 501.80M | 439.55M |
| Receivables | 24.43M | 6.83M | 17.76M | 1.81M | 8.41M | 2.01M | 16.65M | 244.00K | 0 | 834.00K | 1.28M | 2.50M |
| Inventory | 380.00K | 154.00K | 0 | — | — | — | — | — | — | — | — | — |
| Total Current Assets | 1.21B | 839.47M | 916.98M | 977.35M | 886.54M | 956.05M | 1.11B | 1.02B | 1.07B | 638.70M | 628.05M | 561.42M |
| Property, Plant & Equipment | 78.92M | 82.44M | 79.19M | 76.00M | 70.22M | 67.17M | 65.81M | 64.22M | 65.69M | 68.02M | 68.75M | 75.61M |
| Long-Term Investments | 538.32M | 254.72M | 335.05M | 288.82M | 178.20M | 150.69M | 145.06M | 269.17M | 305.36M | 15.38M | 40.53M | 15.47M |
| Total Assets | 1.92B | 1.27B | 1.42B | 1.44B | 1.23B | 1.26B | 1.40B | 1.44B | 1.52B | 808.08M | 824.32M | 740.61M |
| Accounts Payable | 20.51M | 24.71M | 22.34M | 22.08M | 16.23M | 13.94M | 20.37M | 11.58M | 9.47M | 12.97M | 21.51M | 13.80M |
| Short-Term Debt | 27.36M | 44.81M | 41.18M | 17.28M | 14.40M | 12.96M | 11.52M | 11.52M | 11.52M | 11.52M | 10.08M | — |
| Total Current Liabilities | 181.43M | 199.19M | 202.45M | 142.14M | 131.06M | 159.73M | 179.67M | 109.81M | 102.78M | 88.86M | 102.68M | 77.72M |
| Long-Term Debt | 248.20M | 247.21M | 246.38M | 158.75M | 159.06M | 92.03M | 93.23M | 93.02M | 92.83M | 56.82M | 58.38M | 60.88M |
| Total Liabilities | 2.10B | 2.10B | 2.08B | 1.96B | 1.59B | 1.53B | 1.54B | 1.45B | 1.42B | 1.20B | 1.21B | 1.18B |
| Shareholders' Equity | -173.49M | -826.57M | -659.63M | -521.12M | -368.72M | -266.41M | -135.37M | -13.91M | 108.55M | -396.16M | -386.32M | -438.80M |
| Retained Earnings | -3.89B | -3.69B | -3.49B | -3.30B | -3.00B | -2.86B | -2.70B | -2.55B | -2.39B | -2.25B | -2.11B | -1.98B |
| Total Debt | 275.56M | 292.02M | 287.56M | 176.03M | 173.46M | 104.98M | 104.75M | 104.54M | 104.35M | 68.34M | 68.46M | 60.88M |
| Net Cash (Debt) | 890.13M | 526.53M | 594.66M | 786.51M | 684.68M | 833.23M | 971.27M | 907.15M | 952.42M | 550.62M | 546.36M | 478.35M |
| Shares Outstanding | — | — | 122.94M | — | — | — | 118.21M | — | — | — | 101.64M | — |
This table shows 12 quarterly periods of Cytokinetics's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow CYTK's reporting calendar. What is a balance sheet?